Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.795 USD | +0.28% | 0.00% | -21.74% |
01:00pm | Tilray Brands, Inc. Announces the Launch of 'Purple Churro,' by Redecan Cannabis | CI |
May. 30 | Tilray Brands, Inc. Announces Good Supply Launches 'Twisted' All-In-One Vape | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- Low profitability weakens the company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.30% | 1.48B | C- | ||
+43.40% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.57% | 351B | C+ | ||
+19.01% | 328B | B- | ||
+8.01% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+0.30% | 167B | C+ | ||
+6.27% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TLRY Stock
- Ratings Tilray Brands, Inc.